成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

AZD1480

AZD1480是一種新型，ATP競爭性的JAK2抑制劑，無細胞試驗中IC50為0.26 nM，選擇性作用于JAK3和Tyk2，對JAK1的作用較弱。Phase 1。

AZD1480 Chemical Structure

AZD1480 Chemical Structure

CAS: 935666-88-9

規(guī)格 價格 庫存 購買數(shù)量
10mM (1mL in DMSO) 1071.19 現(xiàn)貨
5mg 819.48 現(xiàn)貨
50mg 4671.71 現(xiàn)貨
200mg 12858.3 現(xiàn)貨
1g 43161.3 現(xiàn)貨
更大包裝 有超大折扣

400-668-6834

info@selleck.cn
免費分裝
免費預(yù)溶

AZD1480相關(guān)產(chǎn)品

相關(guān)信號通路圖

JAK Signaling Pathways

JAK信號通路圖

細胞實驗數(shù)據(jù)示例

細胞系 實驗類型 給藥濃度 孵育時間 活性描述 文獻信息
NCI-H82 Apoptosis Assay 0.3/1/3 μM 48 h increases the level of cleaved-Caspase 3 24158701
GLC4 Apoptosis Assay 0.3/1/3 μM 48 h increases the level of cleaved-Caspase 3 24158701
NCI-N592 Apoptosis Assay 0.3/1/3 μM 48 h increases the level of cleaved-Caspase 3 24158701
NCI-H82 Function Assay 0.3/1/3 μM 24 h induces G2/M cell cycle arrest 24158701
GLC4 Function Assay 0.3/1/3 μM 24 h induces G2/M cell cycle arrest 24158701
NCI-N592 Function Assay 0.3/1/3 μM 24 h induces G2/M cell cycle arrest 24158701
CWR22Rv1 Function Assay 800 nM 72 h suppresses IL-6-induced migratory 24577942
DU145? Function Assay 800 nM 72 h suppresses IL-6-induced migratory 24577942
DU145? Function Assay 0-200 nM 1 h? suppresses IL-6-activated Stat3 and ERK1/2 signaling 24577942
MO4 Function Assay 0.5/1/5 μM 6 h inhibits P-STAT3 expression? 25149535
OVCAR-8? Apoptosis Assay 0.5/1/5 μM 48 h induces significant apoptosis at high concerntration 25646015
OVCAR-5? Apoptosis Assay 0.5/1/5 μM 48 h induces significant apoptosis at high concerntration 25646015
OVCAR-8? Cell Viability Assay 0.05-10 μM 72 h reduces cell viability at the concerntration of 5 μM 25646015
OVCAR-5 Cell Viability Assay 0.05-10 μM 72 h reduces cell viability at the concerntration of 5 μM 25646015
A1847 Cell Viability Assay 0.05-10 μM 72 h reduces cell viability at the concerntration of 5 μM 25646015
MOVCAR-5009 Function Assay 0.05-10 μM 24 h reduces phosphorylated STAT3 levels 25646015
MOVCAR-5447 Function Assay 0.05-10 μM 24 h reduces phosphorylated STAT3 levels 25646015
OVCAR-8 Function Assay 0.05-10 μM 24 h reduces phosphorylated STAT3 levels 25646015
OVCAR-5 Function Assay 0.05-10 μM 24 h reduces phosphorylated STAT3 levels 25646015
A1847 Function Assay 0.05-10 μM 24 h reduces phosphorylated STAT3 levels 25646015
UM-22A Function Assay 0.0005-1.6 μM 24 h abrogates IL-6–induced up-regulation of pSTAT3Tyr705?in a dose-dependent manner 25810010
HH5 Function Assay 0.0005-3.8 μM 24 h abrogates IL-6–induced up-regulation of pSTAT3Tyr705?in a dose-dependent manner 25810010
Cal33 Function Assay 0.0005-3.8 μM 24 h abrogates IL-6–induced up-regulation of pSTAT3Tyr705?in a dose-dependent manner 25810010
UMSCC-1 Function Assay 0.0005-1.6 μM 24 h abrogates IL-6–induced up-regulation of pSTAT3Tyr705?in a dose-dependent manner 25810010
LoVo? Function Assay 5 μM 48 h blocks JAK2/STAT3 signaling 25954974
SW620 Function Assay 5 μM 48 h blocks JAK2/STAT3 signaling 25954974
KCNR Apoptosis Assay 0.5/1.0/2.5 μM 24 h induces an increase in caspase 3/7 activity 23531921
SY5Y Apoptosis Assay 0.5/1.0/2.5 μM 24 h induces an increase in caspase 3/7 activity 23531921
Rh18 Apoptosis Assay 0.5/1.0/2.5 μM 24 h induces an increase in caspase 3/7 activity 23531921
TC32 Apoptosis Assay 0.5/1.0/2.5 μM 24 h induces an increase in caspase 3/7 activity 23531921
KCNR Function Assay 0.5/1.0/2.5/5 μM 24 h inhibits both endogenous constitutive and IL-6-induced STAT3 activation 23531921
SY5Y Function Assay 0.5/1.0/2.5/5 μM 24 h inhibits both endogenous constitutive and IL-6-induced STAT3 activation 23531921
Rh18 Function Assay 0.5/1.0/2.5/5 μM 24 h inhibits both endogenous constitutive and IL-6-induced STAT3 activation 23531921
TC32 Function Assay 0.5/1.0/2.5/5 μM 24 h inhibits both endogenous constitutive and IL-6-induced STAT3 activation 23531921
TPC-1 Growth Inhibition Assay 1 μM 0-4 d inhibits cell growth after 2 d treatment 23056499
MZ-CRC1? Growth Inhibition Assay 1 μM 0-5 d inhibits cell growth after 1 d treatment 23056499
TT? Growth Inhibition Assay 1 μM 0-4 d inhibits cell growth after 1 d treatment 23056499
TPC-1 Function Assay 1 μM 72 h induces G1 blockage 23056499
MZ-CRC1? Function Assay 1 μM 72 h induces G1 blockage 23056499
TT? Function Assay 1 μM 72 h induces G1 blockage 23056499
MZ-CRC1? Apoptosis Assay 1 μM 48 h induces apoptosis 23056499
TT? Apoptosis Assay 1 μM 48 h induces apoptosis 23056499
HD-LM2 Function Assay 0.1/0.5/1/5 μM 72?h inhibits STAT3, STAT5 and STAT6 phosphorylation 22829094
L-428 Function Assay 0.1/0.5/1/5 μM 72?h inhibits STAT3, STAT5 and STAT6 phosphorylation 22829094
KM-H2 Function Assay 0.1/0.5/1/5 μM 72?h inhibits STAT3, STAT5 and STAT6 phosphorylation 22829094
L-540 Function Assay 0.1/0.5/1/5 μM 72?h inhibits STAT3, STAT5 and STAT6 phosphorylation 22829094
HD-LM2 Apoptosis Assay 1/5 μM 72?h induces apoptosis 22829094
L-428 Apoptosis Assay 1/5 μM 72?h induces apoptosis 22829094
KM-H2 Apoptosis Assay 1/5 μM 72?h induces apoptosis 22829094
L-540 Apoptosis Assay 1/5 μM 72?h induces apoptosis 22829094
U251-MG Function Assay 1 μM 0-16 h inhibits constitutive STAT-3 and JAK2 activation 22027691
U87-MG Function Assay 1 μM 0-16 h inhibits constitutive STAT-3 and JAK2 activation 22027691
4C8 Function Assay 1 μM 0-16 h inhibits constitutive STAT-3 and JAK2 activation 22027691
U251-MG Growth Inhibition Assay 1/10 μM 24/48/72 h inhibits cell proliferation at a concentration of 10 μM 22027691
U87-MG Growth Inhibition Assay 1/10 μM 24/48/72 h inhibits cell proliferation at a concentration of 10 μM 22027691
4C8 Growth Inhibition Assay 1/10 μM 24/48/72 h inhibits cell proliferation at a concentration of 10 μM 22027691
U266 Apoptosis Assay 0.5-2 μM 48/72 h induces apoptosis dose dependently 21164517
Kms.11 Apoptosis Assay 0.5-2 μM 48/72 h induces apoptosis dose dependently 21164517
8226 Apoptosis Assay 0.5-2 μM 48/72 h induces apoptosis dose dependently 21164517
SW620 Cell cycle assay 3.3 uM 24 hrs Cell cycle arrest in human SW620 cells assessed as accumulation at G2/M phase at 3.3 uM after 24 hrs by flow cytometry 21138246
HEL Function assay 0.3 uM 5 mins Inhibition of Stat5 phosphorylation in human HEL cells at 0.3 uM after 5 mins by Western blotting 21138246
HEL Function assay 0.3 uM 30 to 60 mins Inhibition of Stat5 phosphorylation in human HEL cells at 0.3 uM after 30 to 60 mins by Western blotting 21138246
BA/F3 Antitumor assay 30 mg/kg 12 hrs Antitumor activity against mouse BA/F3 cells expressing Tel-JAK2 xenografted in NCr mouse assessed as reduction of phosphorylated Stat5 level in spleen at 30 mg/kg, po after 12 hrs by Western blotting 21138246
HEL Function assay 0.3 uM 5 mins Inhibition of Stat3 phosphorylation in human HEL cells at 0.3 uM after 5 mins by Western blotting 21138246
HEL Function assay 0.3 uM 30 to 60 mins Inhibition of Stat3 phosphorylation in human HEL cells at 0.3 uM after 30 to 60 mins by Western blotting 21138246
Hs578T Function assay 1 uM 24 hrs Inhibition of STAT3C-mediated transcription in human Hs578T cells at 1 uM after 24 hrs by luciferase reporter gene assay 24978112
NCI-H1975 Function assay 0.003 to 3 uM 2 hrs Inhibition of JAK1 in human NCI-H1975 cells assessed as reduction in STAT3 phosphorylation at 0.003 to 3 uM after 2 hrs by Western blot analysis 26614408
PALJDL Cell Viability Assay 72 h IC50=2.4 μM 25504635
AKRSL Cell Viability Assay 72 h IC50＞10 μM 25504635
PCI-15B Growth Inhibition Assay 72 h EC50=0.99 ± 1.74 μM 25810010
PCI-52 Growth Inhibition Assay 72 h EC50=1.00 ± 0.09 μM 25810010
OSC19 Growth Inhibition Assay 72 h EC50=1.26 ± 0.20 μM 25810010
UM-22A Growth Inhibition Assay 72 h EC50=1.32 ± 0.39 μM 25810010
UM SCC-1 Growth Inhibition Assay 72 h EC50=1.67 ± 0.42 μM 25810010
686LN Growth Inhibition Assay 72 h EC50=2.05 ± 1.33 μM 25810010
UM-22B Growth Inhibition Assay 72 h EC50=2.66 ± 0.24 μM 25810010
Cal33 Growth Inhibition Assay 72 h EC50=3.37 ± 0.75 μM 25810010
HN5 Growth Inhibition Assay 72 h EC50=3.81 ± 1.99 μM 25810010
HD-LM2 Growth Inhibition Assay 72?h IC50=7.844 μM 22829094
L-428 Growth Inhibition Assay 72?h IC50=7.947 μM 22829094
KM-H2 Growth Inhibition Assay 72?h IC50=1.308 μM 22829094
L-540 Growth Inhibition Assay 72?h IC50=8.216 μM 22829094
SET2 Growth inhibition assay 48 hrs Growth inhibition of human SET2 cells expressing Jak2 V617F mutant after 48 hrs by MTS assay, GI50 = 0.016 μM. 21138246
SET2 Function assay 1 hr Inhibition of Stat3 phosphorylation in human SET2 cells after 1 hr by Western blotting, IC50 = 0.023 μM. 21138246
SET2 Function assay 1 hr Inhibition of Stat5 phosphorylation in human SET2 cells after 1 hr by Western blotting, IC50 = 0.025 μM. 21138246
HEL Function assay 1 hr Inhibition of Stat5 phosphorylation in human HEL cells after 1 hr by Western blotting, IC50 = 0.041 μM. 21138246
UKE1 Growth inhibition assay 48 hrs Growth inhibition of human UKE1 cells expressing Jak2 V617F mutant after 48 hrs by MTS assay, GI50 = 0.054 μM. 21138246
BA/F3 Growth inhibition assay 48 hrs Growth inhibition of mouse BA/F3 cells expressing Tel-JAK2 kinase after 48 hrs by MTS assay, GI50 = 0.06 μM. 21138246
HEL Function assay 1 hr Inhibition of Stat3 phosphorylation in human HEL cells after 1 hr by Western blotting, IC50 = 0.08 μM. 21138246
HEL Growth inhibition assay 48 hrs Growth inhibition of human HEL cells expressing Jak2 V617F mutant after 48 hrs by MTS assay, GI50 = 0.39 μM. 21138246
BA/F3 Growth inhibition assay 48 hrs Growth inhibition of mouse BA/F3 cells expressing Tel-JAK1 kinase after 48 hrs by MTS assay, GI50 = 0.7 μM. 21138246
BA/F3 Growth inhibition assay 48 hrs Growth inhibition of mouse BA/F3 cells expressing Tel-Tyk2 kinase after 48 hrs by MTS assay, GI50 = 2 μM. 21138246
BA/F3 Growth inhibition assay 48 hrs Growth inhibition of mouse BA/F3 cells expressing Tel-JAK3 kinase after 48 hrs by MTS assay, GI50 = 2.1 μM. 21138246
UKE1 Function assay 1 hr Inhibition of Stat5 phosphorylation in human UKE1 cells after 1 hr by Western blotting 21138246
HEL 92.1.7 Function assay 2 hrs Inhibition of JAK2 in human HEL 92.1.7 cells assessed as reduction in STAT5 phosphorylation after 2 hrs by Western blot analysis 26614408
IMR32 Growth Inhibition Assay IC50=0.66 μM 23531921
NGP Growth Inhibition Assay IC50=0.56 μM 23531921
AS Growth Inhibition Assay IC50=1.53 μM 23531921
BE2 Growth Inhibition Assay IC50=0.71 μM 23531921
SY5Y Growth Inhibition Assay IC50=0.36 μM 23531921
KCNR Growth Inhibition Assay IC50=0.46 μM 23531921
HEK293 Growth Inhibition Assay IC50=8.67 μM 23531921
ARPE19 Growth Inhibition Assay IC50=24.38 μM 23531921
RC165N Apoptosis Assay IC50=2.083 μM 23942095
DU145 Apoptosis Assay IC50=3.517 μM 23942095
PC-3 Apoptosis Assay IC50=1.755 μM 23942095
CWR22Pc Apoptosis Assay IC50=0.438 μM 23942095
CWR22Rv1? Apoptosis Assay IC50=0.482 μM 23942095
DMS114 Growth Inhibition Assay IC50=0.73 μM 24158701
H1173 Growth Inhibition Assay IC50=2.39 μM 24158701
H526 Growth Inhibition Assay IC50=3.08 μM 24158701
GLC4 Growth Inhibition Assay IC50=1.79 μM 24158701
H82 Growth Inhibition Assay IC50=1.37 μM 24158701
N592 Growth Inhibition Assay IC50=0.84 μM 24158701
LAN5 Growth Inhibition Assay IC50=1.04 μM 23531921
RH18 Growth Inhibition Assay IC50=1.42 μM 23531921
RH30 Growth Inhibition Assay IC50=1.25 μM 23531921
RH17 Growth Inhibition Assay IC50=2.51 μM 23531921
RH28 Growth Inhibition Assay IC50=4.28 μM 23531921
RH36 Growth Inhibition Assay IC50=5.37 μM 23531921
RH41 Growth Inhibition Assay IC50=0.48 μM 23531921
RD Growth Inhibition Assay IC50=4.32 μM 23531921
TC32 Growth Inhibition Assay IC50=3.85 μM 23531921
TC71 Growth Inhibition Assay IC50=4.33 μM 23531921
Ba/F3 Function assay Inhibition of Stat5 phosphorylation in mouse Ba/F3 cells expressing TEL-Jak2, IC50 = 0.046 μM. 21138246
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells 29435139
Saos-2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells 29435139
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells 29435139
Rh41 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells 29435139
點擊查看更多細胞系數(shù)據(jù)

生物活性

產(chǎn)品描述 AZD1480是一種新型，ATP競爭性的JAK2抑制劑，無細胞試驗中IC50為0.26 nM，選擇性作用于JAK3和Tyk2，對JAK1的作用較弱。Phase 1。
特性 AZD1480為治療多發(fā)性骨髓瘤的潛在新型治療劑。
靶點
JAK2 [1]
(Cell-free assay)
0.26 nM
體外研究(In Vitro)
體外研究活性 5μM AZD1480誘導(dǎo)細胞周期停在G2/M期，且通過抑制Aurora激酶而誘導(dǎo)細胞死亡。[1]AZD1480是JAK2的有效抑制劑，作用于人類多發(fā)性骨髓瘤細胞，可以抑制生長，存活，F(xiàn)GFR3 和 STAT3信號，及下游靶點，包括 Cyclin D2。在低微摩爾濃度時，AZD1480抑制細胞增殖和誘導(dǎo)骨髓瘤細胞系凋亡。[2]AZD1480 作用于人和鼠神經(jīng)膠質(zhì)瘤細胞，有效抑制組成型和誘導(dǎo)型JAK1, JAK2, 及STAT-3的磷酸化作用 ，結(jié)果導(dǎo)致細胞增殖降低，且誘導(dǎo)凋亡。[3]AZD1480是有效的ATP競爭性的JAK1/2激酶小分子抑制劑，可抑制STAT3磷酸化和腫瘤生長，這種抑制存在STAT3依賴性。AZD1480通過影響腫瘤的微環(huán)境而抑制腫瘤血管生成和局部轉(zhuǎn)移。[4]
激酶實驗 激酶實驗
在有buffer(包括50 mM HEPES pH 為7.3, 1 mM DTT, 0.01% Tween-20, 50 μg/ml BSA,及10 mM MgCl2)的條件下，使用重組Jak1, Jak2, 或Jak3進行AZD1480抑制效果研究。在昆蟲細胞中，Jak3酶表達為氮端GST融合蛋白，且通過谷胱甘肽親和及尺寸排除色譜來純化Jak3酶。加入AZD1480 (10點劑量反應(yīng), 重復(fù)三次, 8.3 μM 到0.3 nM )，使用1.5 μM 肽底物(Jak1:FITC-C6-KKHTDDGYMPMSPGVA-NH2, Jak2和Jak3: FAM-SRCtide)，及各自ATP Km (Jak1: 55 μM, Jak2: 15 μM, Jak3: 3 μM)，ATP濃度為5 mM，進行酶實驗。分離磷酸化和未磷酸化的肽段，使用Caliper LC3000系統(tǒng)計算抑制百分率。
細胞實驗 細胞系 Renca或786-O細胞，鼠內(nèi)皮細胞和脾CD11b+/c?骨髓細胞, HUVECs
濃度 1 μM
孵育時間 48或24小時
方法 Renca或786-O細胞懸浮在含5%FBS的DMEM培養(yǎng)基中,按每孔5×103個細胞接種在96孔板上，使細胞粘附，實驗組用AZD1480，對照組用DMSO，處理48小時。通過MTS實驗測定細胞活力。使用Mikrotek Laborsysteme在490nm處測定吸光值。鼠內(nèi)皮細胞和脾CD11b+/c? 骨髓細胞從攜帶腫瘤的鼠中富集得到，培養(yǎng)在含5% FBS的RPMI-1640培養(yǎng)基上。HUVECs 培養(yǎng)在膠原1包被的含完全培養(yǎng)基的板上。用DMSO和不同劑量AZD1480處理所有細胞，持續(xù)24小時。手動計算細胞數(shù)而測定細胞活力。所有實驗重復(fù)三次。
實驗圖片 檢測方法 檢測指標 實驗圖片 PMID
Western blot p-STAT3 / STAT3 / p-JAK2 / JAK2 p-STAT1 / STAT1 / p-STAT5 / STAT5 / p-STAT6 / STAT6 p-ERK / ERK / p-p38 / p38 / SOCS3 / p-SHP2 / SHP2 22027691
Immunofluorescence pSTAT5 30140255
Growth inhibition assay Cell proliferation Cell viability 22027691
體內(nèi)研究(In Vivo)
體內(nèi)研究活性 AZD1480作用于人類實體瘤模型和多發(fā)性骨髓瘤模型，抑制 STAT3磷酸化。[1]在體內(nèi), AZD1480抑制皮下移植瘤的生長，且通過抑制STAT3活性提高攜帶顱內(nèi)惡性膠質(zhì)瘤(GBM)的鼠壽命，說明AZD1480抑制JAK/STAT3通路的藥理學(xué)可以用于研究治療攜帶顱內(nèi)惡性膠質(zhì)瘤的患者。[3]AZD1480抑制骨髓細胞的肺浸潤和肺轉(zhuǎn)移瘤。AZD1480作用于人類移植瘤模型降低血管生成和代謝。[4]AZD1480抑制含有STAT活性的人類實體瘤的生長。[5]
動物實驗 Animal Models 雌性BALB/c和無胸腺鼠(NCR? nu/nu) (7-8周大)
Dosages 每天一次，劑量為50 mg/kg；或者每天兩次，劑量為30 mg/kg
Administration 口服飼喂
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01219543 Terminated
Solid Tumour|Advanced Solid Malignancies|Child-Pugh A to B7 Advanced Hepatocellular Carcinoma|EGFR and/or ROS Mutant NSCLC|Lung Metastasis Carcinoma|Gastric Cancer
AstraZeneca
 November 2010 Phase 1
NCT01112397 Terminated
Solid Malignancies
AstraZeneca
 April 2010 Phase 1

化學(xué)信息&溶解度

分子量 348.77 分子式

C14H14ClFN8
CAS號 935666-88-9 SDF Download AZD1480 SDF
Smiles CC1=CC(=NN1)NC2=NC(=NC=C2Cl)NC(C)C3=NC=C(C=N3)F
儲存條件(自收到貨起)

體外溶解度
批次：

DMSO : 70 mg/mL ( (200.7 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO)

Water : Insoluble

Ethanol : Insoluble

摩爾濃度計算器

體內(nèi)溶解度
批次：

現(xiàn)配現(xiàn)用，請按從左到右的順序依次添加，澄清后再加入下一溶劑

 動物體內(nèi)配方計算器

實驗計算

摩爾濃度計算器

質(zhì)量 濃度 體積 分子量

動物體內(nèi)配方計算器（澄清溶液）

第一步：請輸入基本實驗信息（考慮到實驗過程中的損耗，建議多配一只動物的藥量）

mg/kg g μL 只

第二步：請輸入動物體內(nèi)配方組成（配方適用于不溶于水的藥物；不同批次藥物配方比例不同，請聯(lián)系Selleck為您提供正確的澄清溶液配方）

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結(jié)果：

工作液濃度： mg/ml；

DMSO母液配制方法： mg 藥物溶于μL DMSO溶液（母液濃度mg/mL，注：如該濃度超過該批次藥物DMSO溶解度，請先聯(lián)系Selleck）；

體內(nèi)配方配制方法：取μL DMSO母液，加入μL PEG300，混勻澄清后加入μL Tween 80，混勻澄清后加入μL ddH2O，混勻澄清。

體內(nèi)配方配制方法：取μL DMSO母液，加入μL Corn oil，混勻澄清。

注意：1. 首先保證母液是澄清的；
2.一定要按照順序依次將溶劑加入，進行下一步操作之前必須保證上一步操作得到的是澄清的溶液，可采用渦旋、超聲或水浴加熱等物理方法助溶。

技術(shù)支持

在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段，您遇到的任何問題，均可以通過撥打我們的熱線電話400-668-6834，或者技術(shù)支持郵箱tech@selleck.cn，直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。

操作手冊

如果有其他問題，請給我們留言。

* 必填項

請輸入您的姓名
請輸入您的郵箱地址 請輸入一個有效的郵箱地址
請寫點東西給我們
Tags: buy AZD1480 | AZD1480 supplier | purchase AZD1480 | AZD1480 cost | AZD1480 manufacturer | order AZD1480 | AZD1480 distributor
在線咨詢
聯(lián)系我們